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Abstract This meta-analysis aimed to compare the effi-
cacy and adverse events, either serious or mild/moderate,
of all generic versus brand-name cardiovascular medicines.
We searched randomized trials in MEDLINE, Scopus,
EMBASE, Cochrane Controlled Clinical Trial Register,
and ClinicalTrials.gov (last update December 1, 2014).
Attempts were made to contact the investigators of all
potentially eligible trials. Two investigators independently
extracted and analyzed soft (including systolic blood
pressure, LDL cholesterol, and others) and hard efficacy
outcomes (including major cardiovascular adverse events
and death), minor/moderate and serious adverse events. We
included 74 randomized trials; 53 reported C1 efficacy
outcome (overall sample 3051), 32 measured mild/mod-
erate adverse events (n = 2407), and 51 evaluated serious
adverse events (n = 2892). We included trials assessing
ACE inhibitors (n = 12), anticoagulants (n = 5),
antiplatelet agents (n = 17), beta-blockers (n = 11), cal-
cium channel blockers (n = 7); diuretics (n = 13); statins
(n = 6); and others (n = 3). For both soft and hard efficacy
outcomes, 100 % of the trials showed non-significant dif-
ferences between generic and brand-name drugs. The
aggregate effect size was 0.01 (95 % CI -0.05; 0.08) for
soft outcomes; -0.06 (-0.71; 0.59) for hard outcomes. All
but two trials showed non-significant differences in
mild/moderate adverse events, and aggregate effect size
was 0.07 (-0.06; 0.20). Comparable results were observed
for each drug class and in each stratified meta-analysis.
Overall, 8 serious possibly drug-related adverse events
were reported: 5/2074 subjects on generics; 3/2076 subjects
on brand-name drugs (OR 1.69; 95 % CI 0.40–7.20). This
meta-analysis strengthens the evidence for clinical equiv-
alence between brand-name and generic cardiovascular
drugs. Physicians could be reassured about prescribing
generic cardiovascular drugs, and health care organization
about endorsing their wider use.
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Introduction
Because generic medicines are produced by multiple man-
ufacturers after the patent of the brand-name equivalent
expires, most of them are significantly less expensive than
their brand-name counterparts [1]. To control pharmaceuti-
cal expenses, in the last two decades many payers and pro-
viders have encouraged the use of generic drugs, whose
market share sharply increased and exceeded 40 % of the
market volume in most developed countries in 2011 [2].
Generic drugs contain the same active ingredients as the
original brand-name formulations and they aim to be
identical to them or within an acceptable bioequivalent
range in terms of their pharmacokinetic and pharmacody-
namic characteristics. By extension, generics are consid-
ered identical in dose, strength, route of administration,
safety, efficacy, and intended use [3].
Besides bioequivalence, the crucial assumption of iden-
tical health benefits of generics and brand-name drugs is
based upon a few systematic reviews [1, 4–7]. In particular,
in the context of cardiovascular diseases, which represents
the first cause of disease burden in EU,USA and globally [8],
only two meta-analyses directly compared the health out-
comes of generic and brand-name medicines [4, 7]. One
meta-analysis focused on clopidogrel only [7]. The other
meta-analysis considered all drugs and included data on 30
randomized controlled trials (RCTs) [4]. However, it was
published in 2008, and the results of dozens of RCTs
reporting at least one efficacy or safety outcomes have been
made available since then. Also, only efficacy outcomes
from randomized trials had been considered in the prior
meta-analysis, and the comparisons between generic and
brand-name medicines lacked statistical power for several
drug classes. For example, the conclusions on antiplatelet
agents, ACE inhibitors and statins were based upon only 50,
23 and 71 subjects, respectively [4]. Finally, 16 of the 30
included trials had follow-up shorter than 48 h, a duration
that allows bioequivalence measurements but provides very
little information for safety or efficacy outcomes.
We updated and expanded previous work and carried
out a meta-analysis of RCTs comparing the efficacy and
adverse events, either serious or mild/moderate, of all
generic versus brand-name cardiovascular drugs.
Methods
Search, study inclusion criteria and quality
assessment
We included RCTs directly comparing at least one brand-
name drug and at least one of its generic versions, and
reporting at least one efficacy or safety outcome to treat or
control cardiovascular diseases in humans, including vital
signs (e.g. blood pressure), laboratory parameters used in
clinical practice (e.g. low-density lipoprotein), mortality,
and indices of morbidity. Trials focusing and reporting
only on bioequivalence measures (e.g. drug serum con-
centration, time until maximum concentration, area under
the curve based on serum concentration as a function of
time) were retrieved to search whether safety and/or effi-
cacy outcomes were also reported or could be retrieved
from their investigators. Trials on biologic products (any
medicinal product manufactured in or extracted from bio-
logical sources; e.g. vaccines) were excluded, as well as
observational studies. No language or date restrictions were
used.
The search was initially made online in MEDLINE,
Scopus, EMBASE, Cochrane Controlled Clinical Trial
Register (CCCTR), and ClinicalTrials.gov (last update
December 1, 2014). The bibliographies of all relevant
articles including reviews were then reviewed for further
references. When it was not possible to extract any safety
or efficacy outcome from a study, several attempts to
contact the corresponding author were made. We planned
to include also results that were posted in ClinicalTrials.-
gov and not published in peer-review journals. The search
string was adjusted for each database while maintaining a
common overall architecture. We used various combina-
tions of the following terms related to four main domains:
‘‘generic* OR non-proprietary OR nonproprietary OR non-
brand name drug’’ (title/abstract) AND ‘‘brand-name drug
OR innovator OR patent drug OR proprietary drug’’ (all
fields) AND ‘‘cardiovascular disease* OR coronary heart
disease OR myocardial infarction OR acute coronary syn-
drome OR heart failure OR congestive heart disease OR
blood pressure OR cholesterol OR hypertension OR
hypercholesterolemia OR atherosclerosis OR antihyper-
tensive* OR antiarrhythmic* OR beta blocker* OR cal-
cium channel blocker* OR ace inhibitor* OR angiotensin
receptor blocker* OR diuretic* OR statin*’’ (title/abstract)
AND ‘‘random*’’ (all fields). Several alternative strings
were used in PubMed by two investigators, independently,
in order to enhance the sensitivity. Details on the adopted
search strings are available in Additional Appendix S1.
Although we could not exactly reproduce the search by
Kesselheim et al. [4], as not enough details were available,
we used the same main subject heading domains and, as a
proof of principle for the sensitivity of our searches, we
retrieved all 35 trials [9–46] found in the previous meta-
analysis [4]. Indeed, the only substantial difference
between the two searches were the online databases: we
searched Scopus, CCCTR, and ClinicalTrials.gov in addi-
tion to MEDLINE and EMBASE.
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We assessed aspects of the reported methodological
quality of each study using the Cochrane risk of bias tool:
generation of allocation sequences, allocation concealment,
blinding, type of analysis, missing or selective outcome
reporting and other sources of bias [47].
Outcomes and data analysis
A standardized effect size (Cohen’s d) and its 95 % con-
fidence intervals (95 % CIs) were computed for each study
using the methodology detailed elsewhere [48–50]. In
brief, the standardized effect sizes compare the difference
in effect between the study groups divided by the standard
deviation of this difference. This measure is independent of
the measurement used, sample size, and standard deviation
of the outcome measure, and allows the aggregation of
different outcomes across studies to obtain effect sizes for
each cardiovascular drug class as well as an aggregate
effect size for all studies included in the meta-analysis [4,
51]. If the repeated measures correlation of a cross-over
trial was not reported, we assumed a coefficient of 0.5 [4].
For continuous outcomes, if the standard deviation of the
mean difference between the pre-post differences of the
groups under comparison were not reported, we used the
largest standard deviation of the mean differences of the
groups [52]. For categorical outcomes, the natural loga-
rithms of single study odds ratios were first computed and
then divided by 1.81 to obtain the equivalent d [50]. If the
sample size at the end of follow-up was not clearly spec-
ified, we extracted the baseline sample. An effect size
lower than 0.2 should be considered very small; small if
ranging from 0.2 to 0.5; medium from 0.5 to 0.8; and large
if greater than 0.8 [51]. In our analysis, a positive effect
size favors generics.
Two investigators independently extracted all outcomes.
For efficacy outcomes, we initially selected for extraction
the outcomes that were most closely related to the sup-
posed clinical effect of the drug. For ACE inhibitors or
Angiotensin receptor blockers, beta-blockers, calcium-
channel blockers, and other drugs, we used systolic blood
pressure reduction from baseline to the end of follow-up.
For statins, we used LDL cholesterol reduction. For anti-
coagulants, we used the percentage of subjects within
therapeutic INR range. For antiplatelet agents, we used
bleeding time, or the variation in platelet aggregation
inhibition, when bleeding time was not reported. For
diuretics, we used the variation in urinary sodium excre-
tion, or variation in urine volume, when urinary sodium
secretion was not available, or systolic blood pressure,
when both the above outcomes were not available. If the
first choice outcomes were not available, we tried to con-
tact authors for more information. In case of no response
(as for all attempts), we extracted the other efficacy
outcome among those listed above. In any case, all reported
outcomes of any study were extracted, and the authors of
all studies were contacted to request additional information
of outcomes and on published or unpublished trials. Also,
we requested information from the authors of the poten-
tially eligible trials that were excluded because only
bioequivalence outcome were reported.
For safety outcomes, we recorded separately
mild/moderate and serious adverse events (any medical
occurrence that resulted in death, life-threatening medical
conditions, persistent or substantial disability or incapacity,
or admission to hospital). When information was available,
we only extracted the adverse events that were possibly
related to the drug (as defined by the authors).
Hard efficacy outcomes (e.g. major cardiovascular
events—MACE—or death) were extracted and combined
separately from soft outcomes (e.g. systolic blood pressure
or LDL reduction). Efficacy outcomes were reported at
more than one follow-up point in several trials. We always
extracted the data referred to the longest follow-up, except
for five trials [33, 35, 40, 53, 54]. In these trials, the drug
was administered only once, and efficacy data were
reported at several time-points, some of which were distant
from the estimated duration of the effect (based upon the
half-life reported in study); we extracted the data referred
to the time-point that was closer to the estimated duration
of the drug effect (although, in all cases, the results of the
various time-points did not vary substantially). Four other
trials reported efficacy and safety data at different time
points [25, 30, 34, 55]: we accordingly reported different
follow-up durations for the same study in the meta-re-
gression analyses on efficacy and safety outcomes. Finally,
one trial compared two doses (25 and 50 mg) of generic
and brand-name captopril [56]: the results were similar
with both doses, and we extracted the data relative to the
50 mg dose. The details of the outcome extraction for each
included study are reported in Additional Table S1.
The effect sizes of efficacy outcomes and mild/moderate
adverse events were combined using a random-effect,
generic inverse variance approach [47], and statistical
heterogeneity was quantified using the I2 metric [57]. In
case of limited data I2 metric 95 % confidence intervals are
typically large [58] and thus inferences on the magnitude of
the statistical heterogeneity should be cautious. Data on
serious adverse events were combined using individual
data random-effect logistic regression, with single study as
the cluster unit, to avoid the exclusion of the many trials
with zero events in both groups [47, 59]. The combined
datasets with individual data were reconstructed using
published 2X2 tables. The protocol of the review is
available online as supporting information.
Several stratified meta-analyses were made to explore
the potential influence of several a priori selected variables
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(health status: healthy, if defined so by the authors or
without any major disease, or non-healthy; sample size:
B30, 31–99, C100; study location: USA, Europe, Asia or
other; design: cross-over or classic parallel group; follow-
up duration: B1, 2–27, C28 days; blinding: open-label or
single-blinded, double-blinded; funding: generic manufac-
turer, brand-name manufacturer, other funding, not repor-
ted). In addition to stratification, we used meta-regression
with multiple covariates to explore potential predictors of
the summary estimate of risk [60]. To reduce potential
overfitting and false positive results, the number of vari-
ables included in both final and intermediate models
(during modelling) was limited to 1 tenth of the included
studies [57].
The impact of potential publication bias could not be
evaluated as trials in this context are typically aimed at
producing non-significant rather than significant results and
indeed studies rarely had statistically significant differ-
ences in outcomes of interest. Standardized effect sizes and
95 % CIs for continuous outcomes were computed and
combined using RevMan 5.3 (Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2014).
Stata version 13 (Stata Corp., College Station, TX, 2013)
was used to perform meta-regression and logistic regres-
sion analysis.
Results
Characteristics of eligible studies
Of the 745 papers initially retrieved (online PRISMA flow
diagram), we included 74 randomized trials comparing
generic vs brand-name drugs against cardiovascular dis-
eases [9–13, 15–40, 42, 43, 53–56, 61–96]: 53 trials eval-
uated at least one efficacy outcome (overall sample 3051),
32 trials measured mild or moderate adverse events
(n = 2407), and 52 reported on serious adverse events
(n = 2952). Among the 53 trials including at least one
efficacy outcome, we could extract hard outcomes (MACE
or death) from 3 trials only, and soft outcomes from 52
trials. The safety outcomes of four trials were not published
in peer-reviewed journal but were posted on ClinicalTri-
als.gov [61, 62, 65, 66]. 38 reports were excluded because
only bioequivalence outcomes were reported or relevant
outcome data could not be extracted. We attempted to
contact all investigators, and thanks to their answers we
were able to retrieve four additional trials [72, 73, 78, 81],
and to add the data on mild/moderate [83] or serious [75]
adverse events for two studies. The complete list of the
excluded trials is available in Additional Appendix S2.
The main characteristics of each included trial have
been reported in Table 1: the drug-classes under evaluation
were ACE inhibitors or Angiotensin receptor blockers (12
trials), anticoagulants (n = 5), antiplatelet agents (n = 17),
beta-blockers (n = 11), calcium channel blockers (n = 7);
diuretics (n = 13); statins (n = 6); and others including
alpha-blockers (n = 1); heparin (n = 1), and ezetimibe
(n = 1).
Of the 74 trials, 39 trials were performed in Asian
countries, 15 in Europe and 18 in America; 24 studies had a
follow-up duration equal or longer than 4 weeks; 58 trials
had a cross-over design; the sample size was C100 in 10
trials, while 40 studies included 30 subjects or less; 37
trials were funded by the generic manufacturer, and only
11 of the 37 studies published after 2005 had the protocol
registered online (11/27 from 2010, the year in which the
first trial with a registered protocol was published).
All outcomes evaluated in each trial are listed in
Additional Table S1: the extracted outcomes varied across
single studies, however an outcome that was closely related
to the supposed clinical effect of the drug was extracted in
all trials with at least one efficacy outcome, with two
exceptions that were excluded [14, 41]. The mean differ-
ence between groups in systolic blood pressure change
from baseline was extracted in 18 of the 18 trials with
efficacy outcomes on beta-blockers, ACE inhibitors (or
Angiotensin receptor blockers) and calcium channel
blockers. Also, the variation in LDL cholesterol was
extracted from all studies on statins.
As shown in Additional Table S2, based on their
reporting 7 of the 70 included trials were at low risk of bias
for at least 5 of the 6 methodological characteristics
included in Cochrane risk-of-bias assessment tool, while 14
‘‘scored’’ 1 or 0. As regards the single items, the random
sequence generation and allocation concealment were
unclear or inappropriate for 35 and 60 studies, respectively.
Only 24 trials were double-blinded, and 27 had low risk of
selective reporting.
Efficacy
Overall, 52 trials including 2609 subjects were included in
the meta-analysis evaluating soft efficacy outcomes
(Table 1; Fig. 1), and 3 trials including 667 subjects were
included in the meta-analysis evaluating hard efficacy
outcomes (Fig. 2). For both soft and hard outcomes, all
RCTs (100 %) showed non-significant differences between
generic and brand-name drugs. The aggregate effect size
was 0.01 (95 % CI -0.05; 0.08) for soft outcomes; -0.06
(95 % CI -0.71; 0.59) for hard outcomes, both indicating
no difference between generic and brand-name drugs.
Similar results were observed for each drug class and in
each stratified meta-analysis (Table 2). There was no large
statistical heterogeneity between studies in any of the
comparisons. No covariate was significantly associated
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with effect size in meta-regression analysis (Additional
Table S3).
Mild or moderate adverse events
Overall, 32 trials including 2407 subjects were included in
the meta-analysis evaluating mild or moderate adverse
events. All but 2 trials showed non-significant differences
between generic and brand-name drugs, and aggregate
effect size was 0.07 (95 % CI -0.06; 0.20; Table 2;
Fig. 3). Comparable results were observed for each drug
class and in each stratified meta-analysis (Table 2). The
statistical heterogeneity between studies was low or mod-
erate in most comparisons. A significant difference in the
risk of mild or moderate adverse events favoring generic
versus brand-name drugs was found in two stratified meta-
analyses (trials not reporting the sponsor; trials of inter-
mediate follow-up duration). However, none of such
covariates was significantly associated with effect size in
meta-regression analysis, either univariate or multivariate
(Additional Table S4).
Serious adverse events
Overall, 8 serious possibly drug-related adverse events were
reported in 52 studies: 5 events among the 2134 subjects who
assumed generics (819 from parallel-group RCTs and 1315
from cross-over RCTs; rate = 2.34 %); 3 events among the
2136 subjects who assumed brand-name drugs (815 from
parallel-group RCTs and 1321 from cross-over RCTs;
rate = 1.40 %). All but 1 event were reported by industry-
sponsored Asian studies, published after the year 2005, with
follow-up longer than 27 days [22, 39, 92, 96]. No deaths
were reported, and all cases made a full recovery. The meta-
analysis on serious adverse events showed no significant
differences between generic and brand-name medicines
(odds ratio for generics: 1.69; 95 % CI 0.40; 7.20). No
stratified analysis produced significant results.
Discussion
Every clinician is repeatedly exposed to anecdotal evidence
from patients, colleagues, and of course company repre-
sentatives, claiming that generic drugs are not as effective
and/or safe as their branded counterparts [97–99]. A
number of observational studies [4, 5, 100, 101] show good
results with generics, however their use is still modest in
several countries [102, 103]. Brand name antiplatelet
agents, ACE inhibitors, Angiotensin receptor blockers and
statins have combined sales which exceed $100 billion
yearly and dominate the cardiovascular pharmaceutical
market [104–106]. The only other published meta-analysisT
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Study or Subgroup
1.1.1 ACE inhibitors
Portoles 2004
Carranza 2005
Kim (ACE) 2009
Jia 2010
Oigman 2013
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.67, df = 4 (P = 0.95); I² = 0%
Test for overall effect: Z = 0.61 (P = 0.54)
1.1.2 Anticoagulants
Neutel 1998
Handler 1998
Lee 2005
Pereira 2005
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.95, df = 3 (P = 0.81); I² = 0%
Test for overall effect: Z = 0.71 (P = 0.48)
1.1.3 Antiplatelet agents
Rao 2003
Ashraf 2005
Mijares 2008
Kim (Plat) 2009
Shim 2010
Muller 2010
Srimahachota 2012
Tsoumani (Ang) 2012
Oberhansli 2012
Tsoumani (Exp) 2012
Park 2013
Seo 2014
Komosa 2014
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 6.74, df = 12 (P = 0.87); I² = 0%
Test for overall effect: Z = 0.18 (P = 0.86)
1.1.4 Beta-Blockers
El-Sayed 1989
Biswas 1989
Carter 1989
Sarkar 1995
Chiang 1995
Bongers 1999
Cuadrado 2002
Mirfazaelian 2003
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.59, df = 7 (P = 0.98); I² = 0%
Test for overall effect: Z = 0.01 (P = 0.99)
1.1.5 Calcium channel blockers
Usha 1997
Saseen 1997
Park 2004
Mignini 2007
Kim 2007
Kim 2008
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.63, df = 5 (P = 0.90); I² = 0%
Test for overall effect: Z = 0.31 (P = 0.75)
1.1.6 Diuretics
Grahnen 1984
Garg 1984
Martin 1984
Pan 1984
Meyer 1985
Singh 1987
Sharoky 1989
Kaojarern 1990
Awad 1992
Murray 1997
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 5.94, df = 9 (P = 0.75); I² = 0%
Test for overall effect: Z = 0.58 (P = 0.56)
1.1.7 Statins
Wiwanitkit 2002
Assawawitoontip 2002
Kim 2010
Boh 2011
Kim 2013
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.63, df = 4 (P = 0.62); I² = 0%
Test for overall effect: Z = 0.54 (P = 0.59)
1.1.8 Others
Tsai 2007
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.38 (P = 0.70)
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 21.79, df = 51 (P = 1.00); I² = 0%
Test for overall effect: Z = 0.38 (P = 0.70)
Test for subgroup differences: Chi² = 1.63, df = 7 (P = 0.98), I² = 0%
IV, Random, 95% CI
0.09 [-0.50, 0.68]
0.09 [-0.51, 0.69]
0.16 [-0.25, 0.57]
-0.12 [-0.66, 0.42]
0.06 [-0.33, 0.45]
0.07 [-0.15, 0.28]
0.11 [-0.22, 0.44]
-0.10 [-0.59, 0.39]
0.21 [-0.34, 0.76]
0.35 [-0.88, 1.58]
0.09 [-0.15, 0.33]
0.00 [-0.62, 0.62]
0.09 [-0.41, 0.59]
-0.08 [-0.70, 0.54]
-0.07 [-0.48, 0.34]
0.05 [-0.46, 0.56]
-0.42 [-1.05, 0.21]
0.51 [-0.06, 1.08]
0.12 [-0.75, 0.99]
-0.02 [-0.38, 0.34]
0.04 [-0.66, 0.74]
-0.07 [-0.41, 0.27]
0.21 [-0.19, 0.61]
-0.16 [-0.70, 0.38]
0.01 [-0.12, 0.15]
-0.11 [-0.91, 0.69]
0.33 [-0.60, 1.26]
0.00 [-0.80, 0.80]
0.00 [-0.51, 0.51]
0.08 [-0.50, 0.66]
0.03 [-0.36, 0.42]
0.00 [-0.57, 0.57]
-0.40 [-1.21, 0.41]
0.00 [-0.21, 0.21]
0.41 [-0.40, 1.22]
0.11 [-0.87, 1.09]
-0.20 [-0.85, 0.45]
-0.02 [-0.59, 0.55]
-0.02 [-0.31, 0.27]
-0.10 [-0.45, 0.25]
-0.03 [-0.22, 0.16]
0.16 [-0.82, 1.14]
0.13 [-0.56, 0.82]
-0.14 [-0.95, 0.67]
0.09 [-1.15, 1.33]
-0.49 [-1.15, 0.17]
-0.13 [-1.18, 0.92]
0.08 [-0.64, 0.80]
-0.60 [-1.66, 0.46]
-0.35 [-0.97, 0.27]
0.31 [-0.24, 0.86]
-0.07 [-0.31, 0.17]
0.31 [-0.35, 0.97]
0.22 [-0.23, 0.67]
-0.09 [-0.35, 0.17]
0.14 [-0.19, 0.47]
0.01 [-0.22, 0.24]
0.04 [-0.10, 0.18]
-0.06 [-0.37, 0.25]
-0.06 [-0.37, 0.25]
0.01 [-0.05, 0.08]
Year
2004
2005
2009
2010
2013
1998
1998
2005
2005
2003
2005
2008
2009
2010
2010
2012
2012
2012
2012
2013
2014
2014
1989
1989
1989
1995
1995
1999
2002
2003
1997
1997
2004
2007
2007
2008
1984
1984
1984
1984
1985
1987
1989
1990
1992
1997
2002
2002
2010
2011
2013
2007
DifferenceMeanStd.DifferenceMeanStd.
IV, Random, 95% CI
-1 -0.5 0 0.5 1
Favours brand-name Favours generic
Fig. 1 Meta-analysis
evaluating the clinical efficacy
(soft outcomes) of generic vs
brand-name drugs against
cardiovascular diseases
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to-date on this topic, although rigorously done, only
included 50, 23 and 71 subjects in the evaluation of anti-
platelet agents, ACE inhibitors and statins, respectively [4].
Also, most of these subjects had been followed for
\2 days, only efficacy outcomes were combined, and
many trials have been published later on [32, 54, 55, 63,
64, 67–72, 74–81, 83, 84, 86–96]. In the present meta-
analysis all 53 RCTs evaluating efficacy outcomes found
no significant differences between generic and brand-name
cardiovascular drugs. Unsurprisingly, the combined esti-
mate of efficacy did not approach significance for any
drug-class and in any stratified analysis, all of which
showed low or moderate between-study heterogeneity.
Similarly, the risk of mild or moderate adverse events was
comparable between generics and branded medicines in 26
out of 29 trials, and combining trial results no evidence
emerged of a superiority of one drug type over the other.
Concerning serious adverse events, the results of 47 studies
showed again a similar risk with both generics and pro-
prietary drugs, however the number of events was sparse,
and further data must be collected to achieve satisfactory
statistical power.
Taken together, these results suggest that using generic
instead of brand-name cardiovascular drugs does not imply
a loss in either efficacy or safety. These findings provide a
more solid confirmation to observational analyses and to
the previous meta-analysis on randomized trials, with
respect to which we included from 10 to 15 times more
subjects consuming statins, ACE inhibitors and antiplatelet
agents, and included 24 versus 7 trials with a follow-up of
4 weeks or more [4].
Our study has some potential limitations that must be
mentioned. First, approximately half of the included stud-
ies were bioequivalence trials with cross-over design, short
follow-up duration and small samples, sometimes includ-
ing disproportionately young and healthy participants.
Although the validity of such trials to demonstrate differ-
ences in clinical outcomes may be debated, it is worth
noting that similar results were obtained combining trials
with a parallel-group design, larger samples, longer follow-
up, and including only unhealthy subjects, and age was not
associated with the effect estimate in meta-regression
analysis. In any case, age, multimorbidity, polypharmacy
and a greater degree of compromised metabolic function
might have influenced the bioequivalence of generic drugs
and, due to limited evidence from RCTs, the influence of
these parameters cannot be studied. Second, most of the
included studies did not report the funding source or were
sponsored by the generic manufacturer, thus it is very
difficult to draw any firm conclusions about the potential
impact of any sponsorship bias, even if the stratified
analyses and meta-regression revealed no clear patterns.
Given that the vast majority of trials in this field have very
low power to detect significant differences, it is unlikely
that a lot of significant differences have been generated and
then suppressed by sponsors. Third, we combined together
different outcomes of efficacy, and adverse events that
were heterogeneously measured. However, within several
drug-classes (ACE inhibitors or Angiotensin receptor
blockers, anticoagulants, beta-blockers, calcium-channel
blockers and statins) the extracted efficacy outcomes were
identical. Moreover, for the other drug-classes the alter-
native efficacy outcomes that could be extracted from
single studies never showed a different result (Additional
Table S1), and both soft and hard outcomes were always
non-significant in single studies. Fourth, almost two-thirds
of all studies were at high-risk of selective outcome
reporting, less than one-third of the trials published after
2005 had their protocol registered online, and most cross-
over studies failed to accommodate the within-individual
differences in the analysis. Therefore, on one side there is
the need of an in-depth analysis of the publication pattern
of generic trials starting from clinical trial registries, as a
relevant proportion of RCTs likely remained unpublished
[107]. On the other side, more journals in the field should
adhere to ICMJE recommendation of trial protocol regis-
tration in a public trials registry as a condition for publi-
cation [108]. Fifth, it must be noted that more studies on
drugs with narrow therapeutic interval like antiarrhythmics
are strongly needed, and that even though we found no
differences between generics and brand-name drugs, there
might be differences concerning adverse events between
Study or Subgroup
1.2.3 Antiplatelet agents
Khosravi 2011
Park 2013
Seo 2014
Subtotal (95% CI)
Heterogeneity: Tau² = 0.14; Chi² = 2.86, df = 2 (P = 0.24); I² = 30%
Test for overall effect: Z = 0.18 (P = 0.86)
Total (95% CI)
Heterogeneity: Tau² = 0.14; Chi² = 2.86, df = 2 (P = 0.24); I² = 30%
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Not applicable
Weight
72.3%
13.4%
14.3%
100.0%
100.0%
IV, Random, 95% CI
0.15 [-0.04, 0.34]
-1.25 [-2.87, 0.37]
0.00 [-1.56, 1.56]
-0.06 [-0.71, 0.59]
-0.06 [-0.71, 0.59]
Year
2011
2013
2014
ecnereffiDnaeM.dtSecnereffiDnaeM.dtS
IV, Random, 95% CI
-2 -1 0 1 2
Favours brand-name Favours generic
Fig. 2 Meta-analysis
evaluating the clinical efficacy
(hard outcomes: MACE or
death) of generic versus brand-
name drugs against
cardiovascular diseases
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two generic drugs. Finally, the overall meta-analytic esti-
mate combining the results of different drug classes is
typically problematic and should be interpreted with cau-
tion, because for some drugs the influence of the prepara-
tion (inert binders, fillers, manufacturing process) might be
bigger than for other drugs, even though the mechanism of
the drug is the same for generic and brand name drugs.
Unfortunately, we could not dissect the potential influence
of the preparation as this information was generally not
available across the included studies.
Table 2 Results of meta-analyses comparing the efficacy and safety of generic versus brand-name drugs against cardiovascular diseases
Efficacy (soft outcomes) I2 (%) Mild or moderate adverse events I2 (%)
n (N) ES (95 % CI) Upper (95 % CI) n (N) ES (95 % CI) Upper (95 % CI)
Overall 52 (2609) 0.01 (-0.05; 0.08) 0 (32) 32 (2407) 0.07 (-0.06; 0.20) 15 (45)
Drug class
ACE inhibitors or ARBs 5 (262) 0.07 (-0.15; 0.28) 0 (79) 8 (456) 0.10 (-0.20; 0.41) 38 (72)
Anticoagulants 4 (136) 0.09 (-0.15; 0.33) 0 (85) 3 (196) 0.19 (-0.12; 0.50) 0 (90)
Antiplatelet agents 13 (732) 0.01 (-0.12; 0.15) 0 (57) 7 (519) -0.10 (-0.40; 0.19) 0 (71)
Beta-blockers 8 (181) 0.00 (-0.21; 0.21) 0 (68) 4 (123) 0.23 (-0.10; 0.57) 0 (85)
Calcium channel blockers 6 (374) -0.03 (-0.22; 0.16) 0 (75) 4 (356) 0.09 (-0.23; 0.42) 0 (85)
Diuretics 10 (135) -0.07 (-0.31; 0.17) 0 (62) 2 (43) 0.27 (-1.81; 2.36) 91 (–)
Statins 5 (746) 0.04 (-0.10; 0.18) 0 (79) 3 (671) -0.06 (-0.40; 0.27) 16 (91)
Others 1 (43) -0.06 (-0.37; 0.25) – 1 (43) 0.05 (-0.43; 0.53) –
Health status
Healthy 23 (488) -0.06 (-0.19; 0.06) 0 (45) 17 (557) 0.14 (-0.13; 0.40) 38 (65)
Non-healthy 29 (2121) 0.05 (-0.03; 0.13) 0 (41) 15 (1850) 0.05 (-0.09; 0.19) 0 (53)
Continent
America 11 (258) 0.03 (-0.14; 0.21) 0 (60) 7 (402) 0.11 (-0.16; 0.37) 36 (73)
Europe 12 (586) 0.02 (-0.13; 0.17) 0 (60) 8 (365) 0.15 (-0.15; 0.46) 24 (65)
Asia 27 (1651) 0.01 (-0.07; 0.10) 0 (44) 16 (1545) 0.02 (-0.16; 0.21) 4 (52)
Others 2 (114) -0.15 (-0.67; 0.37) 49 (–) 1 (95) -0.22 (-0.67; 0.23) –
Funding
Industry—generic 20 (1721) 0.01 (-0.08; 0.09) 0 (47) 22 (2009) 0.05 (-0.08; 0.18) 10 (44)
Industry—brand-name 2 (25) -0.03 (-0.89; 0.83) 55 (–) 0 (0) – –
Other funding 7 (321) 0.02 (-0.21; 0.24) 0 (71) 3 (75) -0.35 (-0.99; 0.29) 0 (90)
Not reported 22 (552) -0.01 (-0.12; 0.14) 0 (46) 7 (323) 0.48 (0.04; 0.92) 28 (69)
Follow-up duration
B1 day 22 (484) 0.00 (-0.13; 0.14) 0 (46) 4 (115) 0.23 (-0.72; 1.81) 73 (91)
2–27 days 10 (299) -0.02 (-0.19; 0.16) 0 (62) 14 (501) 0.16 (0.09; 0.41) 10 (48)
C28 days 20 (1826) 0.02 (-0.06; 0.11) 0 (48) 14 (1791) 0.04 (-0.09; 0.18) 0 (55)
Study design
Parallel-group 14 (1693) 0.02 (-0.08; 0.12) 0 (55) 12 (1622) -0.03 (-0.19; 0.14) 0 (58)
Cross-over 38 (916) 0.00 (-0.09; 0.10) 0 (37) 20 (805) 0.15 (-0.04; 0.34) 27 (58)
Blinding
Open-label or single-blind 30 (1557) 0.01 (-0.07; 0.10) 0 (40) 25 (1452) 0.09 (-0.05; 0.23) 0 (44)
Double-blind 22 (1052) 0.02 (-0.09; 0.12) 0 (46) 7 (955) 0.07 (-0.22; 0.36) 52 (80)
Sample size
B30 28 (512) -0.01 (-0.14; 0.12) 0 (42) 11 (249) 0.19 (-0.23; 0.60) 46 (73)
31–99 17 (892) 0.06 (-0.05; 0.17) 0 (51) 13 (738) 0.13 (-0.04; 0.30) 0 (57)
C100 7 (1205) -0.01 (-0.13; 0.10) 0 (71) 8 (1420) -0.01 (-0.19; 0.18) 10 (71)
A positive effect size favors generics
ES effect size, OR odds ratio, CI confidence interval, n number of trials, (N) number of participants, ARBs angiotensin II receptor blockers
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Study or Subgroup
1.3.1 ACE inhibitors
Portoles 2004
Spinola 2009
Kim (ACE) 2009
Larouche 2010 (2)
Larouche 2010 (1)
Carlson 2010 (2)
Jia 2010
Oigman 2013
Subtotal (95% CI)
Heterogeneity: Tau² = 0.07; Chi² = 11.23, df = 7 (P = 0.13); I² = 38%
Test for overall effect: Z = 0.67 (P = 0.50)
1.3.2 Anticoagulants
Handler 1998
Weibert 2000
Lee 2005
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.13, df = 2 (P = 0.94); I² = 0%
Test for overall effect: Z = 1.22 (P = 0.22)
1.3.3 Antiplatelet agents
Rao 2003
Mijares 2008
Kim (Plat) 2009
Suh 2011
Srimahachota 2012
Park 2013
Komosa 2014
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 4.72, df = 6 (P = 0.58); I² = 0%
Test for overall effect: Z = 0.68 (P = 0.49)
1.3.4 Beta-Blockers
Bongers 1999
Cuadrado 2002
Bus-Kwasnik 2012
Liu 2013
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.64, df = 3 (P = 0.89); I² = 0%
Test for overall effect: Z = 1.36 (P = 0.17)
1.3.5 Calcium channel blockers
Kim 2007
Mignini 2007
Kim 2008
Liu 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.86, df = 3 (P = 0.41); I² = 0%
Test for overall effect: Z = 0.57 (P = 0.57)
1.3.6 Diuretics
Garg 1984
Almeida 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 2.06; Chi² = 10.86, df = 1 (P = 0.0010); I² = 91%
Test for overall effect: Z = 0.26 (P = 0.80)
1.3.7 Statins
Kim 2010
Boh 2011
Kim 2013
Subtotal (95% CI)
Heterogeneity: Tau² = 0.01; Chi² = 2.37, df = 2 (P = 0.31); I² = 16%
Test for overall effect: Z = 0.38 (P = 0.70)
1.3.8 Others
Tsai 2007
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Total (95% CI)
Heterogeneity: Tau² = 0.02; Chi² = 36.53, df = 31 (P = 0.23); I² = 15%
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Chi² = 3.56, df = 7 (P = 0.83), I² = 0%
IV, Random, 95% CI
1.13 [-0.09, 2.35]
0.46 [0.07, 0.85]
0.09 [-0.39, 0.57]
-0.30 [-1.11, 0.51]
-0.28 [-0.78, 0.22]
0.49 [-0.37, 1.35]
-0.63 [-2.42, 1.16]
-0.18 [-0.84, 0.48]
0.10 [-0.20, 0.41]
0.19 [-0.33, 0.71]
0.22 [-0.19, 0.63]
0.00 [-1.12, 1.12]
0.19 [-0.12, 0.50]
0.63 [-1.17, 2.43]
-0.49 [-1.35, 0.37]
0.62 [-1.16, 2.40]
-0.08 [-0.43, 0.27]
0.65 [-1.14, 2.44]
-1.25 [-2.87, 0.37]
0.07 [-1.50, 1.64]
-0.10 [-0.40, 0.19]
0.26 [-0.17, 0.69]
0.44 [-0.56, 1.44]
0.41 [-0.96, 1.78]
0.00 [-0.73, 0.73]
0.23 [-0.10, 0.57]
-0.33 [-1.03, 0.37]
0.40 [-0.37, 1.17]
0.20 [-0.23, 0.63]
-0.63 [-2.44, 1.18]
0.09 [-0.23, 0.42]
1.36 [0.37, 2.35]
-0.77 [-1.56, 0.02]
0.27 [-1.81, 2.36]
-0.70 [-1.58, 0.18]
0.02 [-0.39, 0.43]
0.05 [-0.44, 0.54]
-0.06 [-0.40, 0.27]
0.05 [-0.43, 0.53]
0.05 [-0.43, 0.53]
0.07 [-0.06, 0.20]
Year
2004
2009
2009
2010
2010
2010
2010
2013
1998
2000
2005
2003
2008
2009
2011
2012
2013
2014
1999
2002
2012
2013
2007
2007
2008
2009
1984
2011
2010
2011
2013
2007
DifferenceMeanStd.DifferenceMeanStd.
IV, Random, 95% CI
-2 -1 0 1 2
Favours brand-name Favours generic
Fig. 3 Meta-analysis
evaluating the risk of mild or
moderate adverse events of
generic versus brand-name
drugs against cardiovascular
diseases
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Conclusions
The present meta-analysis confirmed the substantial clini-
cal equivalence between brand-name and generic cardio-
vascular drugs. On one side, this finding is based upon a
suboptimal evidence: very few studies used hard outcomes
and followed patients for more than 3 months, and many
trials were conducted in healthy volunteers. On the other
side, the relatively large randomized sample size, the
inclusion of many trials with a follow-up longer than
4 weeks, the stability of the results, and the inclusion of
adverse events in the analyses may provide a more solid
reassurance to the scientific community, possibly con-
tributing to reduce the claims and mistrust towards generic
medications [109]. Although generic prices also may sub-
stantially raise following opportunistic behaviors [110], the
growing availability as generic products of blockbuster
drugs is likely to produce several USD billions of savings
[111, 112]. Physicians could be reassured about prescribing
generic cardiovascular drugs to patients, and health care
organizations about endorsing their larger use.
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